AWM
SRNE

Apollon Wealth Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Apollon Wealth Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11,834
Closed -$81K – 377
2020
Q4 		$81K Buy
+11,834
New +$95.1K 0.02% 197
2020
Q3 		– Sell
-889
Closed -$6K – 728
2020
Q2 		$6K Buy
+889
New +$3.4K ﹤0.01% 551

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Apollon Wealth Management's SRNE Position: Q1 2021 in Review

Apollon Wealth Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2021, closing a stake of 11,834 shares — an estimated $81K sold.

Apollon Wealth Management first reported a position in SRNE in Q2 2020 and held it in 2 quarters. The position peaked at $81K in Q4 2020. 231 funds tracked by Wall St. Rank hold SRNE as of Q1 2021.

  • Apollon Wealth Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Apollon Wealth Management sold 11,834 Sorrento Therapeutics, Inc. shares in Q1 2021, an estimated $81K.
  • Apollon Wealth Management first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 2 quarters.
  • Apollon Wealth Management's Sorrento Therapeutics, Inc. position peaked at $81K in Q4 2020.
  • 231 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2021.

Based on Apollon Wealth Management's 13F filing for Q1 2021, filed 17 May 2021.